Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Covigenix VAX-002
- Development stage
- Phase 2
- Lead developer
- Entos Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Covigenix VAX-002 is a plasmid DNA vaccine developed as a booster for COVID-19, specifically targeting the currently circulating omicron strains of SARS-CoV-2. It is formulated using Entos Pharmaceuticals' proprietary Fusogenix proteo-lipid vehicle (PLV) delivery platform, which enables efficient intracellular delivery of the DNA payload encoding key SARS-CoV-2 antigens. The vaccine aims to stimulate robust and durable immune responses and is designed to be fridge-stable, making it suitable for global distribution including in developing countries. Covigenix VAX-002 builds on previous candidates (VAX-001 and VAX-001-1b) and is currently being evaluated in Phase 1/2 clinical trials for safety, optimal dosing, and immunogenicity as a COVID-19 booster[1][2][3][5][6].
- Brand names
- Covigenix VAX-002
- Other names
- Covigenix VAX-002
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Covigenix VAX-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covigenix VAX-002.